ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cannabidiol

Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.

Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.

Drug pageCannabidiol: every studyMany companies study it; this page follows only the 64 they lead. All 316 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 17, 201964 company-led studies, 8 open or runningNext primary completion: Aug 1, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticalsits history only315 open or runningphase 4since Oct 17, 2019Oct 7, 2010Aug 1, 2027phase 4 · NCT05044819
INSYS Therapeuticsits history only50 open or runningphase 3since Dec 12, 2014Dec 12, 2014none ahead
Radius Pharmaceuticalsits history only50 open or runningphase 3since Jan 26, 2018Jul 22, 2016none ahead
Cardiol Therapeutics41 open or runningphase 3since Nov 2, 2020Nov 2, 2020none ahead
Pure Greenits history only40 open or runningphase 2since Sep 10, 2019Sep 10, 2019none ahead
Canopy Growthits history only30 open or runningphase 2since Aug 29, 2019Aug 29, 2019none ahead
Botanix Pharmaceuticalsits history only20 open or runningphase 2since Jun 19, 2018Jun 19, 2018none ahead
Stero Biotechsits history only20 open or runningphase 2since Mar 18, 2019Mar 18, 2019none ahead
Avecho Biotechnologyits history only11 open or runningphase 3since Apr 23, 2023Apr 23, 2023Sep 30, 2027phase 3 · NCT05840822
Bod Australiaits history only10 open or runningphase 2since Dec 20, 2021Dec 20, 2021none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Research UK and Benuvia Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cardiol Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2016Named cannabidiolINNProposed as its International Nonproprietary Name in WHO's List 115 · before, GWP42003-P, GWP42003
  2. Nov 2, 2020First study: phase 3 study in COVID-19First studyNCT04615949 · 90 enrolled · United States, Brazil, Mexico
  3. Sep 25, 2021Phase 2 study in Acute MyocarditisNCT05180240 · 109 enrolled · United States, Brazil, Canada and more
  4. Aug 8, 2022Phase 2 study in PericarditisNCT05494788 · 27 enrolled · United States
  5. Nov 25, 2024Phase 3 study in PericarditisNCT06708299 · 110 planned · United States, Canada, Greece and more

TargetBeta

CNR1 →read by rule
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
RimonabantruleSanofiphase 339
DronabinolruleJazz Pharmaceuticalsphase 320
CRB-913rulecorbus-pharmaceuticals-incphase 11

Studies

All 4 Cardiol Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06708299Pericarditis · United States, Canada, Greece and more3RecruitingSep 21, 2026110
NCT05494788Pericarditis · United States2CompletedJun 15, 202427
NCT05180240Acute Myocarditis · United States, Brazil, Canada and more2CompletedJan 31, 2025109
NCT04615949COVID-19 · United States, Brazil, Mexico3TerminatedNov 30, 202290

How it is read

Names in the registry

  • “GWP42003-P”, 17 entries
  • “Cannabidiol Oral Solution”, 10 entries
  • “Cannabidiol”, 7 entries
  • “CBD”, 5 entries
  • “GWP42003”, 4 entries

Codes read as this program: JZP926.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.